# Crisper Therapeutics AG

**CRSP**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001674416

**A**

**strongest fifth of 369 graded peers in healthcare**

rank 23 of 369; percentile 6.0; sampling error 2.5 points; lower is stronger

A B C D E

**A, the bull**



| Scoreboard | |
|---|---|
| **Profitability** | B/C<br>percentile 39.5 |
| **Solvency** | A<br>percentile 13.6 |
| **Growth and financing** | B/C<br>percentile 39.9 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $2.3B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 12, 2026<br>271 days before the rescan; latest periodic filing 10-Q received Nov 2, 2026 |
| **Last close** | $50.05<br>2026-11-09; market equity $4.9B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 12, 2026*

Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 39.5** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | |
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (10.5%) | (6.6%) | 39.5 | 800 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 13.6** | | | | | |
| Twelve-month failure probability | 0.03% | 0.08% | 15.8 | 248 | 2026-09-30 |
| Altman Z double-prime | 6.42 | (0.35) | 15.2 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 13.32x | 2.95x | 9.7 | 826 | 2025-12-31 |
| **Growth and financing, sleeve percentile 39.9** | | | | | |
| Revenue growth, three-year compound | 43.1% | 10.1% | 15.6 | 411 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | 0.3% | 2.2% | 51.4 | 694 | 2025-12-31 |
| Net share issuance, one year | 11.9% | 2.5% | 52.7 | 629 | 2026-02-10 |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 18 | Intuitive Surgical Inc. (ISRG) | 4.6 | A | |
| 19 | SBC Medical Group Holdings Inc. (SBC) | 5.0 | A | fortress balance sheet |
| 20 | SBC Medical Group Holdings Inc. (SBCWW) | 5.0 | A | fortress balance sheet |
| 21 | Neurocrine Biosciences Inc. (NBIX) | 5.4 | A | |
| 22 | Vericel Corp. (VCEL) | 5.7 | A | |
| 23 | Crispr Therapeutics AG (CRSP) | 6.0 | A | |
| 24 | Ideaya Biosciences, Inc. (IDYA) | 6.2 | A | |
| 25 | AtriCure, Inc. (ATRC) | 6.5 | A | |
| 26 | United Therapeutics Corp. (UTHR) | 6.8 | A | |
| 27 | Gyre Therapeutics, Inc. (GYRE) | 7.1 | A | fortress balance sheet |
| 28 | Hims & Hers Health, Inc. (HIMS) | 7.3 | A | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-11-09 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (13.5%) | (1.9%) | 41 |
| Distance from 52-week high | (19.1%) | (27.5%) | 60 |
| EBIT to enterprise value | (12.7%) | (1.5%) | 30 |
| Free cash flow yield | (7.1%) | (1.0%) | 37 |
| Book value to price | 0.34 | 0.27 | 57 |
| Sales to price | 0.00 | 0.29 | 3 |
| Composite equity issuance, five years | 25.2% | 20.8% | 53 |
| Relative strength against the sector, log excess return | (0.31) | (0.19) | 41 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $192.0M |
| Operating cash flow, four quarters | -$374.6M |
| Months of runway | 6.2 |
| Days since last periodic filing | 8 (10-Q received Nov 2, 2026) |
| Median daily dollar volume, 63 sessions | $69.6M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$581.6M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$345.0M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 3 | assets | us-gaap:Assets | $2.3B | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 4 | assets | us-gaap:Assets | $2.2B | 2024-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 5 | current assets | us-gaap:AssetsCurrent | $2.0B | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $149.1M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.9B | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$664.6M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 9 | book equity | us-gaap:StockholdersEquity | $1.9B | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 10 | liabilities | us-gaap:Liabilities | $343.4M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $3.5M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $37.3M | 2024-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $371.2M | 2023-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.2M | 2022-12-31 | 2025-02-11 | 10-K | 25-017899 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $914,000 | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$142.8M | 2024-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.9M | 2024-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$260.4M | 2023-12-31 | 2026-02-12 | 10-K | 26-048957 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $9.5M | 2023-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$495.7M | 2022-12-31 | 2025-02-11 | 10-K | 25-017899 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $37.2M | 2022-12-31 | 2025-02-11 | 10-K | 25-017899 |
| 22 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $19.5M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 23 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$578.0M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 24 | income tax | us-gaap:IncomeTaxExpenseBenefit | $3.6M | 2025-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 25 | current assets | us-gaap:AssetsCurrent | $1.9B | 2024-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 26 | current liabilities | us-gaap:LiabilitiesCurrent | $87.8M | 2024-12-31 | 2026-02-12 | 10-K | 26-048957 |
| 27 | assets | us-gaap:Assets | $2.2B | 2023-12-31 | 2025-02-11 | 10-K | 25-017899 |
| 28 | assets | us-gaap:Assets | $2.2B | 2022-12-31 | 2024-02-21 | 10-K | 24-017571 |
| 29 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 95,985,312 | 2026-02-10 | 2026-02-12 | 10-K | 26-048957 |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 85,774,474 | 2025-02-07 | 2025-02-11 | 10-K | 25-017899 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.